FDA granted Priority Review to MCNA, developed by Telesta, for the treatment of high-risk, non-muscle invasive bladder cancer patients who are refractory or relapsing from BCG front-line treatment.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
